Michael D Berquist1, Haily K Traxler1, Alyssa M Mahler1, Lisa E Baker2. 1. Department of Psychology, Western Michigan University, Kalamazoo, MI, United States. 2. Department of Psychology, Western Michigan University, Kalamazoo, MI, United States. Electronic address: lisa.baker@wmich.edu.
Abstract
BACKGROUND: Synthetic cathinones, 4-methylmethcathinone (4-MMC) and 3,4-methylenedioxypyrovalerone (MDPV), serve as a substrate or blocker at monoaminergic transporters, respectively, and produce locomotor stimulant effects in rodents. The present study investigated in rats the effects of repeated exposure to 4-MMC, MDPV, or mixtures of the two on the induction of locomotor sensitization and expression of cross-sensitization to cocaine. METHODS: Seventy-two male Sprague-Dawley rats received daily intraperitoneal injections of saline, MDPV (0.5mg/kg), 4-MMC (0.5, 1.0, or 2.0mg/kg) or mixtures of 0.5mg/kg MDPV+4-MMC (0.5, 1.0, or 2.0mg/kg) for seven consecutive days. Locomotor activity was recorded on days 1 and 7 and again after an acute injection of 5mg/kg cocaine following a 10day drug washout period. RESULTS: Rats injected with 0.5mg/kg MDPV, 0.5, 1.0, or 2.0mg/kg 4-MMC, or 2.0mg/kg 4-MMC+0.5mg/kg MDPV displayed time-dependent increases in horizontal activity that were augmented on day 7 compared to day 1. In addition, rats pretreated with 0.5mg/kg MDPV, 2.0mg/kg 4-MMC, or mixtures of 4-MMC+MDPV displayed an enhanced response to cocaine. CONCLUSIONS: Locomotor responses sensitize to MDPV and to certain mixtures of MDPV and 4-MMC following repeated dosing. Furthermore, previous exposure to these substances may produce cross-sensitization to the locomotor stimulant effects of cocaine. Considered together with recent findings that 4-MMC and MDPV have different sites of action, but both influence monoaminergic functioning, further investigations utilizing a variety of behavioral assays may prove informative regarding the abuse liability of synthetic cathinone mixtures.
BACKGROUND: Synthetic cathinones, 4-methylmethcathinone (4-MMC) and 3,4-methylenedioxypyrovalerone (MDPV), serve as a substrate or blocker at monoaminergic transporters, respectively, and produce locomotor stimulant effects in rodents. The present study investigated in rats the effects of repeated exposure to 4-MMC, MDPV, or mixtures of the two on the induction of locomotor sensitization and expression of cross-sensitization to cocaine. METHODS: Seventy-two male Sprague-Dawley rats received daily intraperitoneal injections of saline, MDPV (0.5mg/kg), 4-MMC (0.5, 1.0, or 2.0mg/kg) or mixtures of 0.5mg/kg MDPV+4-MMC (0.5, 1.0, or 2.0mg/kg) for seven consecutive days. Locomotor activity was recorded on days 1 and 7 and again after an acute injection of 5mg/kg cocaine following a 10day drug washout period. RESULTS:Rats injected with 0.5mg/kg MDPV, 0.5, 1.0, or 2.0mg/kg 4-MMC, or 2.0mg/kg 4-MMC+0.5mg/kg MDPV displayed time-dependent increases in horizontal activity that were augmented on day 7 compared to day 1. In addition, rats pretreated with 0.5mg/kg MDPV, 2.0mg/kg 4-MMC, or mixtures of 4-MMC+MDPV displayed an enhanced response to cocaine. CONCLUSIONS: Locomotor responses sensitize to MDPV and to certain mixtures of MDPV and 4-MMC following repeated dosing. Furthermore, previous exposure to these substances may produce cross-sensitization to the locomotor stimulant effects of cocaine. Considered together with recent findings that 4-MMC and MDPV have different sites of action, but both influence monoaminergic functioning, further investigations utilizing a variety of behavioral assays may prove informative regarding the abuse liability of synthetic cathinone mixtures.
Authors: Sinead E Shortall; Alice E Macerola; Rabbi T R Swaby; Rebecca Jayson; Chantal Korsah; Katharine E Pillidge; Peter M Wigmore; Francis J P Ebling; A Richard Green; Kevin C F Fone; Madeleine V King Journal: Eur Neuropsychopharmacol Date: 2012-10-07 Impact factor: 4.600
Authors: David M Wood; Susannah Davies; Shaun L Greene; Jenny Button; David W Holt; John Ramsey; Paul I Dargan Journal: Clin Toxicol (Phila) Date: 2010-11 Impact factor: 4.467
Authors: Edward A Ross; Gary M Reisfield; Mary C Watson; Chris W Chronister; Bruce A Goldberger Journal: Am J Med Date: 2012-06-09 Impact factor: 4.965
Authors: William E Fantegrossi; Brenda M Gannon; Sarah M Zimmerman; Kenner C Rice Journal: Neuropsychopharmacology Date: 2012-11-08 Impact factor: 7.853
Authors: Ryan A Gregg; Christopher S Tallarida; Allen Reitz; Christopher McCurdy; Scott M Rawls Journal: Drug Alcohol Depend Date: 2013-07-23 Impact factor: 4.492
Authors: R López-Arnau; M A Luján; L Duart-Castells; D Pubill; J Camarasa; O Valverde; E Escubedo Journal: Br J Pharmacol Date: 2017-04-06 Impact factor: 8.739
Authors: Michael D Hambuchen; Howard P Hendrickson; Melinda G Gunnell; Samantha J McClenahan; Laura E Ewing; Dillon M Gibson; Michael D Berquist; S Michael Owens Journal: Drug Alcohol Depend Date: 2017-08-08 Impact factor: 4.492
Authors: Taylor A Gentile; Steven J Simmons; Christopher S Tallarida; Shu Su; Slava Rom; Mia N Watson; Allen B Reitz; Raghava Potula; Scott M Rawls Journal: Drug Alcohol Depend Date: 2019-01-31 Impact factor: 4.492
Authors: Callum Hicks; Ryan A Gregg; Sunil U Nayak; Lee Anne Cannella; Giana J Schena; Christopher S Tallarida; Allen B Reitz; Garry R Smith; Scott M Rawls Journal: Psychopharmacology (Berl) Date: 2017-03-01 Impact factor: 4.530
Authors: Chicora F Oliver; Steven J Simmons; Sunil U Nayak; Garry R Smith; Allen B Reitz; Scott M Rawls Journal: Drug Alcohol Depend Date: 2018-03-10 Impact factor: 4.492
Authors: Steven J Simmons; Jonna M Leyrer-Jackson; Chicora F Oliver; Callum Hicks; John W Muschamp; Scott M Rawls; M Foster Olive Journal: ACS Chem Neurosci Date: 2018-05-11 Impact factor: 4.418